CG Oncology, Inc. Common stock Asset Resilience Ratio
CG Oncology, Inc. Common stock asset resilience ratio. CG Oncology, Inc. Common stock (CGON) has an Asset Resilience Ratio of 89.65% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See CGON defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of CG Oncology, Inc. Common stock (2021–2025)
Asset resilience ratio of CG Oncology, Inc. Common stock from 2021 to 2025. This chart shows how CG Oncology, Inc. Common stock's Asset Resilience Ratio has changed over time. Read CG Oncology, Inc. Common stock (CGON) total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down CG Oncology, Inc. Common stock's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see how large is CG Oncology, Inc. Common stock's balance sheet.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $709.66 Million | 89.65% |
| Total Liquid Assets | $709.66 Million | 89.65% |
Asset Resilience Insights
- Very High Liquidity: CG Oncology, Inc. Common stock maintains exceptional liquid asset reserves at 89.65% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
CG Oncology, Inc. Common stock Industry Peers by Asset Resilience Ratio
Compare CG Oncology, Inc. Common stock's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
HLB Co. Ltd
KQ:028300 |
Biotechnology | 3.29% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Shanghai Medicilon Inc
SHG:688202 |
Biotechnology | 6.69% |
|
Blue Jet Healthcare Limited
NSE:BLUEJET |
Biotechnology | 13.81% |
|
Hangzhou Biotest Biotech Co Ltd
SHG:688767 |
Biotechnology | 0.56% |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197 |
Biotechnology | 79.76% |
|
Shenzhen Weiguang Biological Products Co Ltd
SHE:002880 |
Biotechnology | 5.52% |
CG Oncology, Inc. Common stock Asset Resilience Ratio by Year (2021–2025)
CG Oncology, Inc. Common stock asset resilience ratio by year from 2021 to 2025. The table below shows the annual Asset Resilience Ratio data for CG Oncology, Inc. Common stock.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 89.65% | $709.66 Million | $791.59 Million | +25.40pp |
| 2024-12-31 | 64.25% | $484.93 Million | $754.80 Million | -25.77pp |
| 2023-12-31 | 90.02% | $179.41 Million | $199.30 Million | +52.56pp |
| 2022-12-31 | 37.45% | $55.34 Million | $147.75 Million | -- |
| 2021-12-31 | 0.00% | $0.00 | $58.69 Million | -- |
About CG Oncology, Inc. Common stock
CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States. The company's product candidate is cretostimogene, an investigational oncolytic immunotherapy, which is in phase 2 clinical trials of cretostimogene in patients with high-risk NMIBC after BCG failure; a phase 3 clinic… Read more